Retrophin, Inc. (RTRX) Stake Increased by American Century Companies Inc.
American Century Companies Inc. grew its stake in shares of Retrophin, Inc. (NASDAQ:RTRX) by 42.1% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 151,670 shares of the biopharmaceutical company’s stock after acquiring an additional 44,969 shares during the quarter. American Century Companies Inc. owned about 0.40% of Retrophin worth $2,941,000 as of its most recent SEC filing.
Several other large investors also recently added to or reduced their stakes in the company. SG Americas Securities LLC lifted its position in shares of Retrophin by 1.8% during the 2nd quarter. SG Americas Securities LLC now owns 8,167 shares of the biopharmaceutical company’s stock valued at $158,000 after acquiring an additional 146 shares during the period. Legal & General Group Plc lifted its position in shares of Retrophin by 4.3% during the 2nd quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock valued at $168,000 after acquiring an additional 355 shares during the period. American International Group Inc. lifted its position in shares of Retrophin by 7.1% during the 1st quarter. American International Group Inc. now owns 22,300 shares of the biopharmaceutical company’s stock valued at $412,000 after acquiring an additional 1,475 shares during the period. Rhumbline Advisers lifted its position in shares of Retrophin by 4.4% during the 2nd quarter. Rhumbline Advisers now owns 47,454 shares of the biopharmaceutical company’s stock valued at $920,000 after acquiring an additional 2,010 shares during the period. Finally, Credit Suisse AG lifted its position in shares of Retrophin by 8.4% during the 1st quarter. Credit Suisse AG now owns 57,025 shares of the biopharmaceutical company’s stock valued at $1,052,000 after acquiring an additional 4,407 shares during the period.
COPYRIGHT VIOLATION NOTICE: “Retrophin, Inc. (RTRX) Stake Increased by American Century Companies Inc.” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2017/09/13/retrophin-inc-rtrx-stake-increased-by-american-century-companies-inc.html.
A number of research firms have recently weighed in on RTRX. ValuEngine downgraded Retrophin from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. BidaskClub upgraded Retrophin from a “hold” rating to a “buy” rating in a research report on Wednesday, August 16th. Two research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $32.33.
Shares of Retrophin, Inc. (NASDAQ RTRX) opened at 24.00 on Wednesday. The stock’s 50 day moving average price is $22.42 and its 200-day moving average price is $19.56. The company’s market capitalization is $921.24 million. Retrophin, Inc. has a 52-week low of $15.55 and a 52-week high of $25.11.
Retrophin (NASDAQ:RTRX) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.10). Retrophin had a negative return on equity of 7.31% and a negative net margin of 48.74%. The company had revenue of $38.80 million during the quarter, compared to the consensus estimate of $37.36 million. During the same period in the previous year, the business earned $0.07 earnings per share. Retrophin’s revenue was up 16.5% on a year-over-year basis. On average, equities analysts expect that Retrophin, Inc. will post ($1.13) earnings per share for the current year.
In other news, COO Neil F. Mcfarlane sold 1,378 shares of the firm’s stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $22.50, for a total value of $31,005.00. Following the completion of the transaction, the chief operating officer now directly owns 13,622 shares of the company’s stock, valued at $306,495. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.41% of the stock is owned by company insiders.
Retrophin Company Profile
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Stock Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related stocks with our FREE daily email newsletter.